A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Trial Profile

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms INDIGO-1
  • Sponsors Gemphire Therapeutics
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
    • 17 Jan 2018 Status changed from recruiting to active, no longer recruiting, according to a Gemphire Therapeutics meadia relase.
    • 13 Nov 2017 According to a Gemphire Therapeutics media release, the company expects top-line data in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top